Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: GlobeNewswire
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Centessa stockholders will receive $38.00 per share in cash plus contingent value rights worth up to $9.00 per share. The contingent value rights entitle holders to receive up to three milestone payments: $2.00 upon U.S. FDA approval for narcolepsy type 2 treatment, $5.00 for idiopathic hypersomnia approval, and $2.00 for any indication approval before January 1, 2030. All approvals must occur within five years of transaction closing. Centessa insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonab
Show less
Read more
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Centessa Pharmaceuticals (CNTA) was downgraded by Truist Financial Corporation from "buy" to "hold". They now have a $38.00 price target on the stock.MarketBeat
- Centessa Pharmaceuticals (CNTA) had its "neutral" rating reaffirmed by Guggenheim.MarketBeat
- Centessa Pharmaceuticals (CNTA) was downgraded by B. Riley Financial, Inc. from "strong-buy" to "hold".MarketBeat
- Centessa Pharmaceuticals (CNTA) was downgraded by Lifesci Capital from "strong-buy" to "hold".MarketBeat
- Centessa Pharmaceuticals (CNTA) had its "market perform" rating reaffirmed by Leerink Partners. They now have a $40.00 price target on the stock, up from $36.00.MarketBeat
CNTA
Earnings
- 3/31/26 - Miss
CNTA
Sec Filings
- 4/17/26 - Form PREM14A
- 4/13/26 - Form DEFA14A
- 3/31/26 - Form DEFA14A
- CNTA's page on the SEC website